RT Journal Article SR Electronic T1 Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4589 OP 4593 VO 34 IS 8 A1 TOSHIO INUI A1 KAORI MAKITA A1 HIRONA MIURA A1 AKIKO MATSUDA A1 DAISUKE KUCHIIKE A1 KENTARO KUBO A1 MARTIN METTE A1 YOSHIHIRO UTO A1 TAKAHITO NISHIKATA A1 HITOSHI HORI A1 NORIHIRO SAKAMOTO YR 2014 UL http://ar.iiarjournals.org/content/34/8/4589.abstract AB Background: Gc protein-derived macrophage-activating factor (GcMAF) occurs naturally in the human body. It has various functions, such as macrophage activation and antitumor activities. Recently, immunotherapy has become an attractive new strategy in the treatment of cancer. GcMAF-based immunotherapy can be combined with many other therapies. Sonodynamic therapy (SDT) using low-intensity ultrasound is a novel therapeutic modality. Ultrasound has been demonstrated to activate a number of sonosensitive agents allowing for the possibility of non-invasive targeted treatment for both superficial and deep-seated tumors. The current case study demonstrates that GcMAF and SDT can be used in combination with conventional therapies in patients with metastatic cancer, especially where treatment options are limited due to factors such as toxicity. This case study also suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SDT, to be used in combination with GcMAF immunotherapy as a systemic treatment.